How many boxes of pemetinib do I need to take in a month? Standard therapeutic dose analysis

Pemigatinib is a selective FGFR1-3 inhibitor used to treat certain types of cancers that are positive for FGFR gene mutations, especially locally advanced or metastatic cholangiocarcinoma (CCA). The drug blocks the growth and spread of cancer cells by inhibiting the fibroblast growth factor receptor (FGFR) pathway. The following is an analysis of the standard treatment dosage and frequency of use of pemetinib.

For patients with cholangiocarcinoma, the standard treatment dose of pemetinib is usually 4 mg once a day, and is continued for 21 days and then paused for 7 days, forming a 28-day treatment cycle. This cycle generally lasts for several months until significant disease progression or serious adverse reactions occur. Specific dosage and duration of treatment may be adjusted based on patient tolerance and response to treatment.

At the standard dose, patients generally need to take 1box of pemetinib per month. Each box of pemetinib contains 30 capsules, so the patient needs to take 30 capsules within a month, that is, one capsule a day for 21 days, and stop taking the medicine within the subsequent 7 days. If patients follow this treatment plan, they need to purchase 1 box of medication every month.

Although 4 mg is the standard initial dose, some patients may require dose adjustments during treatment due to side effects. For example, doctors may reduce the dose or suspend treatment if a patient develops severe liver function abnormalities or other side effects. The duration and dosage of treatment may vary depending on the patient's specific situation, so patients should communicate closely with their doctor during the treatment process and adjust the treatment plan in a timely manner.

In summary, the treatment regimen for pemetinib is typically 4 mg once daily for 21 days with a break of 7 days. Patients generally need 1box of medication per month. During treatment, patients should be monitored regularly to ensure the effectiveness and safety of the medication.

Reference materials:https://go.drugbank.com/drugs/DB15102